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Abstract
Sperm protein (Sp17) is an attractive target for ovarian cancer (OC) vaccines because of its over-expression in primary as well
as in metastatic lesions, at all stages of the disease. Our studies suggest that a Sp17-based vaccine can induce an enduring
defense against OC development in C57BL/6 mice with ID8 cells, following prophylactic and therapeutic treatments. This is
the first time that a mouse counterpart of a cancer testis antigen (Sp17) was shown to be expressed in an OC mouse model,
and that vaccination against this antigen significantly controlled tumor growth. Our study shows that the CpG-adjuvated
Sp17 vaccine overcomes the issue of immunologic tolerance, the major barrier to the development of effective
immunotherapy for OC. Furthermore, this study provides a better understanding of OC biology by showing that Th-17 cells
activation and contemporary immunosuppressive T-reg cells inhibition is required for vaccine efficacy. Taken together,
these results indicate that prophylactic and therapeutic vaccinations can induce long-standing protection against OC and
delay tumor growth, suggesting that this strategy may provide additional treatments of human OC and the prevention of
disease onset in women with a family history of OC.
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Introduction
Ovarian cancer (OC) is the sixth most common cancer and the
seventh leading cause of cancer death in women [1,2]. Among
OC, 90% of cases are represented by epithelial ovarian cancers
(EOC), arising from the epithelium lining, the ovarian surface or
from inclusion cysts [3,4]. The lethality of OC stems from the
inability to detect the disease at an early organ–confined stage and
from the lack of effective therapies for advanced-stage disease [4].
The late diagnosis and the high rate of resistance to chemotherapy
limit the treatment options available. OC patients with a family
history of OC account for 10% of all cases [5]. Clinical options for
these patients are surgical intervention that leads to infertility, or
chemoprevention with oral contraceptives, often associated with
severe side effects [6,7]. Immunotherapy strategies including
cancer vaccines are considered less toxic and more specific than
current treatments [8], and therefore hold the potential to provide
benefits for OC patients with evident disease and for high-risk OC
patients. Because of their specificity of action, potent and lasting
effects and applicability to virtually any type of tumor, anti-cancer
vaccines are driving the interest of clinical oncologists. A key step
in the development of basic cancer vaccines is the implementation
of vaccination strategies allowing for the consistent induction of
immune responses to tumor antigens. In this respect, the choice of
appropriate antigens, based on both the frequency and the
specificity of their expression in cancer tissues, is of paramount
importance. Cancer/testis antigens (CTA) [9,10,11,12], which
include the Sp17 antigen [9,13,14,15,16], are emerging as
promising candidates for specific immunotherapeutic targets.
CTA represent a subclass of tumor-associated antigens (TAA)
that are non-mutated self antigens expressed or over-expressed in
tumors, and recognized by CD8 T-cells [12,14,17,18,19,20]. The
immunogenic Sp17 protein has been extensively characterized
[10,20,21,22,23,24,25]. Human Sp17 is highly conserved, having
70% homology with rabbit and mouse, and 97% homology with
baboon [25]. Sp17 has a molecular weight of 17.4 KDa, is
encoded by a gene located on chromosome 11, and is aberrantly
expressed in cancers of unrelated histological origin [25] including
multiple myeloma (MM) and OC [21,22]. Sp17-specific CTL,
generated from normal donors, MM and OC patients, have been
shown to kill HLA-matched tumor cell lines and fresh tumor cells
presenting Sp17 epitopes bound to HLA class I molecules
[13,14,21]. These observations support recent studies suggesting
that Sp17 may be a suitable antigen for immunotherapy in OC
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10471[13,25]. Recombinant proteins are commonly used in the
development of antiviral vaccines, and may constitute attractive
candidate antitumor vaccines [11,26,27,28,29]. Professional anti-
gen-presenting cells (APCs) detect pathogens through a variety of
receptors such as the Toll-like receptors (TLR), which recognize
pathogen-associated molecular patterns, including CpG oligo-
deoxynucleotides (CpG ODN) within defined flanking sequences
[27,29,30,31]. CpG motifs, which are frequently expressed in the
bacterial genome but genomically suppressed in vertebrates, are
considered foreign by the immune system and, as a result,
stimulate host defense mechanisms [11,27,29,32,33,34]. CpG-
ODN exhibit great potential in the therapeutic treatment of
cancer due to their ability to activate innate and adaptive
immunity [15,26,27,28]. The TLR9-binding CpG induces
secretion of Th1 cytokines, including IFN-c and TNFa, and
production of antigen-specific IgG2a by B cells [11,12,32,33,34].
In this study, we assessed the prophylactic and therapeutic
immune response elicited by repeated vaccination with Sp17
recombinant protein administered with CpG. We used the murine
ID8 OC cell line, derived from a spontaneous in vitro malignant
transformation of C57BL/6 mouse ovarian surface epithelial cells
to induce tumor growth in mice [34]. Our results show for the first
time that priming with Sp17 protein and CpG is an effective
strategy to induce durable OC therapy.
Results Characterization of Sp17 and MHC-I expression in
ID8 cells
Sp17 mRNA (Figure 1a) and Sp17 protein (Figure 1b) were
detected in the ID8 cell line. Further characterization by immuno-
cytochemistry (ICC) and immunofluorescence (IF) revealed cytoplas-
micand surfacestainingofthesecells(Figure1c).ThecytospinofID8
permeabilized (P) cells exhibits a positive cytoplasmic staining for
Sp17, which was confirmed by IF. Additionally, the non permeabi-
lized (NP) cells also show clear expression through IF (Figure 1c,
lower quadrants) although less by ICC (Figure 1c, upper quadrants).
We further assayed Sp17 surface expression through flow-cytometric
analysis that showed high frequency of Sp17 positive cells (figure 1d).
Similarly, flowcytometry analysis revealed that 60% of ID8 cells
stained positive for MHC-I under basal culture conditions, while
addition of 100 IU/mL IFN-c for 72 hours resulted in 98% MHC-I
positive cells.
In vivo growth of ID8 cells after intraperitoneal injection
Four different doses of ID8 cells (10
5,5 610
5,1 0
6 and 2610
6)w e r e
injected into four groups of mice (five per group) to determine the
optimal dose for induction of tumor/ascites formation. Each set of
experimental inoculations with different doses of ID8 cells was
performed at least three times. Animals from each tumor titration
group were euthanized at different time points, at which a post
mortem examination was conducted on whole animals and dissected
organs (not shown). Optimal tumor growth (based on time and
dimension) was observed with 1 of the 4 conditions (2610
6 ID8 cells)
tested. Figure 2a shows that an i.p. injection of 10
5 ID8 cells
generated a tumor growth after 120 days, whilst 5610
5 ID8 cells
generated a tumor mass/ascites in 90 days (Figure 2b). A dose of 106
cells showed a significant tumor mass/ascites growth by around 60
days(Figure2c)andwhen 26106 ID8cellswere injected,the optimal
tumor mass/ascites was achieved in 40 to 45 days (Figure 2d), and
most deaths occurred between 50–65 days, due either to the tumor
mass or sacrifice to avoid excessive discomfort for the mice. Figure 3a
Figure 1. Analysis of Sp17 expression in ID8 cells. Sp17 mRNA in the murine ID8 tumor cells and in mouse testis (positive control). The mRNA
levels were analyzed by RT-PCR for Sp17 expression. A cellular housekeeping gene, B-actin, was included as a control. A PCR-only control (no RT step)
failed to generate a product, indicating that there was no DNA contamination in the samples. In addition to the RT-PCR (see figure 1a), Western blot
was performed and figure 1b shows the expression of Sp17 at the protein level. The ID8 cell line was further characterized by an
immunocytochemistry (ICC) and immunofluorescence (IF). This figure shows a cytospin of ID8 cells permeabilized (P) and a positive staining for Sp17
at the cytoplasm level. In addition, Sp17 was confirmed by IF in the cytoplasm. Additionally, in figure 1c, the non permeabilized (NP) cells show clear
expression via IF and less by ICC. Panel d shows ID8 characterization for surface expression of Sp17 and MHC-I; isot. ctrl, isotypic control antibody;
percentage indicate positive-staining cells. MHC-I expression was evaluated with or without IFN-g stimulation.
doi:10.1371/journal.pone.0010471.g001
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6) of ID8 cells to
generate tumor mass/ascites (44 mm in width) in less than 45 days,
and a control mouse (20 mm in width) that was not injected with ID8
cells. Figure 3b shows the generation of ascites from an i.p injection of
2610
6ID8cellsinlessthan40days,and alsoshowsadetailedviewof
the peritoneal cavity of a mouse after aspirating 22 mL of ascites,
revealing several metastatic nodes and tumor masses. Furthermore,
figure3confirmsthatthecellsintheperitoneumofmiceinjectedwith
ID8 cells express Sp17 by immunohistochemistry (IHC), while cells
from a mouse without tumor injection were negative for Sp17
(figures 3e, f and g). These results show that Sp17 is expressed in the
ID8 cell line, in vivo. To confirm the tumor mass/ascites originated
from the ID8 cells, specimens of peritoneal, tumor mass/nodes, lung,
liver, ascites, spleen and ovaries were investigated by RT-PCR.
Results are displayed by figure 3d, (representative picture of 5 mice
per experiment, repeated in triplicate) for ID8-injected mice
(figure 3d-1) and control mice (figure 3d-2). Further, a fluorescence-
based localization assay was performed to detect GFP-positive ID8
cells in vivo, and confirmed the peritoneal localization of ID8 cells
(figure 3h).
Immunization regimens and measurement of tumor
growth
The mice were vaccinated with different formulations: Sp17
only; CpG only; and Sp17+ CpG, co-administered. A total of 22
mice were immunized with each vaccine formulation. The mice
were immunized intra-muscularly (i.m) with 50 mg of Sp17 protein
and 20 mg CpG at different time-points as detailed above.
Evaluation of tumor growth and/or ascites was monitored every
three weeks using engineer calipers. Survival was followed until
tumors reached volumes of more than 1,000 mm
3, in accordance
with our Institutional Animal Care and Use Committee
Guidelines.
Evaluation of survival rates after prophylactic and
therapeutic Sp17/CpG vaccinations
Tumor cells were injected 30 days after the 3
rd vaccination of
the prophylactic regimen, or 21 days before the first therapeutic
vaccination. All Sp17+CpG vaccinated mice (100%) were tumor-
free 91 days after tumor injection with ID8 cells (2610
6), whereas
none of the unvaccinated animals (ID8 only) were alive. Figure 4a
displays the survival rates of mice that received prophylactic
immunizations: 12.5% of Sp17+CpG vaccinated mice developed
small tumor masses and ascites after 91 days and died 180 days
after with heavy-load tumors. Moreover, 8% of the vaccinated
mice developed tumors and ascites, and died after 200 days.
However, those tumors were significantly smaller than the ovarian
tumors of the control mice that were vaccinated with PBS only.
The overall survival of Sp17+CpG vaccinated mice was 79% for
over 300 days. Analysis performed by a Log-rank (Mantel-Cox)
Test showed that the overall survival curves were statistically
significant (p,0.0001) for the group vaccinated with Sp17+ CpG
compared with the other vaccine titrations. Figure 4b shows the
survival rates of mice that received therapeutic immunizations.
Figure 2. (a, b, c, d) Tumor growth in ID8-injected mice. Shows the progressive formation of ascites/tumors when i.p. injected with ID8 cells.
ID8 injected mice are shown as m1-m5. Control mice were injected with PBS alone. 1a shows mice injected with 10
5 ID8 cells. The tumors did not
reach a significant size until after 150 days. 2b shows the progressive formation of ascites/tumors when i.p. injected with 5610
5 ID8 cells. The tumors
did not reach a significant size until after 120 days. 2c shows the progressive formation of ascites/tumors when i.p. injected with 10
6 ID8 cells. The
tumors reached a significant size in 90–120 days. 2d shows the progressive formation of ascites/tumors when i.p. injected with 2610
6 ID8 cells. The
tumors reached a significant size in 35–60 days (p,0,0001); a visible enlargement of the mice was noticed at 30 days.
doi:10.1371/journal.pone.0010471.g002
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tumor masses and ascites after 150 days and died after 210 days of
heavy-load tumors. Moreover, less than 10% of the vaccinated
mice developed tumors and ascites, and died after 280 days. The
overall survival of Sp17+CpG vaccinated mice was 80% for over
300 days. Analysis was performed by a Log-rank (Mantel-Cox)
Test and showed that the overall survival curves were statistically
significant (p,0.0001) for the group vaccinated with Sp17+CpG
compared with the other vaccine titrations. Finally, control groups
vaccinated with Sp17 alone and CpG alone showed some to no
protection, that was not statistically significant (figure 4a and 4b).
Measurement of Sp17-specific antibody responses and
cytokine expression by ELISA assay
Analysis of the Sp17-specific antibody response generated in the
vaccinated mice is shown in figure 5. The representative ELISA
assay was performed to analyze the immune response from 3
different vaccine formulations: Sp17+CpG; CpG only; and Sp17
only. Subsequent vaccinations increased specific anti-Sp17
antibody responses compared to the first vaccination. In
figure 5b, we showed a high amount of specific anti-Sp17
antibodies from both Sp17 formulations at 3
rd vaccination. We
explored the repeated vaccination schedule because, in a clinical
setting, patients that are in remission are often continued to be
vaccinated so that there is no recurrence of the tumor. However,
there was a slight decrease of the amount of immune response
compared to the 3
rd vaccination analyses in all three formulations
at the 9
th vaccination (figure 5c) but anti-Sp17 IgG levels in
Sp17+CpG vaccinated group were still statistically higher
compared with the other vaccine formulations (p,0.001). In the
therapeutic regimen group, Sp17+CpG vaccinated mice showed a
significantly higher (p,0.01) production of IgG anti-Sp17 after
270 days, compared with mice treated with the other formulations
(figure 5d). In figure 6 we showed the expression of cytokines at
day 270 (at the 9
th vaccination) in both prophylactic (6a) and
therapeutic (6b) regimens. Serum was collected and analyzed by
ELISA assay (IL-2, IL-4, IL-5, IL-10, IFN-c, TNF-a, GM-CSF)
from mice vaccinated with Sp17+CpG and compared with serum
Figure 3. (a, b, c, d) Analysis of ID8 cells growth and dissemination in vivo. a shows on the left side a control mouse (width of mouse
20 mm) not injected with ID8 cells and on the right side a mouse injected with 26106 ID8 cells after 40 days (width of mouse 44 mm). These mice
represent experiments with similar results. b shows the full peritoneal cavity of ascites induced from an i.p injection of 26106 ID8 in 40 days (left) and
an open view of the cavity with several metastatic nodes and tumor masses (center and right, after aspirating 22 mL of ascites). c shows a
peritoneum negative for Sp17 from a control mouse not injected with ID8 cells. f shows a positive expression of Sp17 on the peritoneum of a mouse
injected with 26106 ID8 cell after 40 days. Testis is the positive control for Sp17 by ICH (g). Figure d shows PCR for Sp17 DNA (and B-actin control): a
tissue panel derived from (1) the organs of a 26106 ID8 injected mouse was positive for Sp17 and a panel of tissues derived from organs of a healthy
mouse revealed no expression of SP17. Positive controls (ID8 and testis) for Sp17 are also shown. Panel h shows in vivo fluorescence pictures of a
control (left) and ID8-injected (right) mouse for the localization of GFP-positive ID8 cells.
doi:10.1371/journal.pone.0010471.g003
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groups, detailed in the text (tumor free, Sp17+CpG vaccinated, unvaccinated, Sp17 or CpG vaccinated). Tumor-bearing mice were i.p. injected with
10
6 ID8 cells for both the prophylactic and therapeutic regimens. Tumor cells were injected 30 days after the 3
rd vaccination of the prophylactic
regimen, or 21 days before the first therapeutic vaccination. In the therapeutic group, the mean difference in weight between tumor-challenged and
tumor-free animals was 10 grams at the beginning of vaccination regimen. Horizontal axis displays time expressed as days from initiation of
treatment. Log-rank test indicated statistically significant difference between unvaccinated and Sp17+CpG vaccinated versus unvaccinated or CpG
treated group (p,0.0001) for both regimens.
doi:10.1371/journal.pone.0010471.g004
Figure 5. Measurement of circulating anti-Sp17 IgG following different vaccinations. Serum from mice undergone different treatments was
collected and analyzed by E.L.I.S.A. for the levels of circulating anti-Sp17 IgG. The X axis shows serial dilutions of serum. a, b and c show results obtained in
the prophylactic vaccination schemes, while d displays the response of mice from the therapeutic regimen. On day 7 (a) the immune response was low for
Sp17. On day 97 (b), the immune response was higher than on day 7. On day 270 (c), the response for Sp17 was little less than on day 97.
doi:10.1371/journal.pone.0010471.g005
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Interestingly, IFN-c from the Sp17+CpG vaccinated mice was
increased by almost two folds compared with the Sp17 vaccinated
animals or around three folds compared with CpG vaccinated
animals (figure 6a and b). In prophylactically vaccinated mice,
TNF-a from Sp17+CpG formulation was increased more than
three folds, as compared with the CpG vaccinated mice and only
two folds compared with Sp17 vaccinated mice (figure 6a). GM-
CSF increments were three folds higher than in CpG vaccinated
mice and less than two folds higher versus Sp17 vaccinated mice
(figure 6a). In therapeutically vaccinated animals, TNF-a from
Sp17+CpG formulation was increased two folds compared with
the CpG and with Sp17 alone formulations (figure 6b). GM-CSF
displayed two-fold and more than one-fold increment compared
with CpG and Sp17 formulations alone, respectively (figure 6b).
Concerning the other cytokines, there was no significant
expression of IL-2, IL-4, IL-5 or IL-10 (figure 6a and b).
Evaluation of CTL antitumor responses
In figure 7a, the ELISPOT IFN-c assay was performed on day
270 (9
th vaccination) using spleen cells of Sp17+CpG prophylac-
tically immunized mice. The strategy of repeated vaccinations in
this animal model is to reflect current human clinical trials. These
results suggest that the frequency of Sp17-specific CTL increased
in the optimal group (Sp17+CpG vaccinated mice) and showed
220630 positive spots in the spleen cells versus the Sp17
vaccinated (184618) and versus the CpG-vaccinated mice that
were as low as 962. In figure 7b, the ELISPOT TNF-a assay was
performed on day 270 (9
th vaccination of prophylactic schedule)
using spleen cells of Sp17+CpG immunized mice (that was the best
formulation for a strong immune response). These results suggest
that the frequency of Sp17-specific CTL increased in the optimal
group (Sp17+CpG vaccinated mice), showing 240635 positive
spots in the spleen cells versus the Sp17 vaccinated only (200631)
and versus the CpG vaccinated mice that were as low as 1262.
Analogously, in the therapeutic vaccination regimen, the frequen-
cy of Sp17-specific CTL increased in the Sp17+CpG group with
259620 IFN-c and 159630 TNF-a positive spots, versus 100620
IFN-c and 70610 TNF-a positive spots in Sp17 and CpG only
formulations, respectively (figure 6c and d). These results overall
suggest a high and specific immune reaction induced by Sp17
when it is co-administered with CpG, regardless of the adopted
vaccination schedule For the cytotoxicity assay by
51Cr-release
measurement, splenocytes were collected at the time of the 1
st,3
rd
and 9
th vaccinations from Sp17 vaccinated mice, CpG vaccinated
mice, and Sp17+CpG vaccinated mice. The CTL assay showed
stronger CTL responses in Sp17+CpG vaccinated mice compared
with the mice immunized with Sp17 or CpG only, both in
prophylactic (figure 8) and therapeutic (figure 9) regimens. Because
in normal ID8 culture conditions in vitro, there is a low expression
of MHC Class I molecules ID8 cells were treated in vitro with IFNc
(100 IU/mL for 72 hours) to induce higher expression levels, as
previously reported (figure 1d, lower panel). ID8 cells activated
with IFN-c were used as better targets for the cytotoxicity assay.
Evaluation of Th-17 and T-reg cell frequency
Figure 10 shows the frequency of Th-17 or T-reg cells in
SP17+CpG vaccinated or control mice splenocytes, collected at
different time points (no tumor: day 0; ID8 only: day 45;
prophylactic and therapeutic day 270).
Both prophylactic and therapeutic vaccinations elicited a
significant increase in Th-17 and a decrease in T-reg cell mean
frequencies (3-and 1.5-folds respectively, fig. 10) compared with
tumor-challenged unvaccinated animals (unpaired t-test p,0.001,
for vaccinated versus control untreated mice). Therapeutic and
prophylactic vaccines consisting in Sp17 or CpG alone also
induced an increment in Th17 frequencies; however, such effect
was not significant (unpaired t-test p.0.05, for SP17- or CpG-
only vaccinated versus control untreated mice). Sp17 or CpG
administered alone reduced T-reg population frequencies at a
higher extent compared with combined Sp17+CpG formulations
in both therapeutic and prophylactic regimens; this reduction was
significant when compared with tumor challenged unvaccinated
mice (unpaired t-test p,0.01), but not when compared with
Sp17+CpG vaccinations (unpaired t-test p.0.05).
Discussion
The lethality of ovarian carcinoma primarily stems from the
inability of physicians to detect the disease at the early organ–
confined and usually asymptomatic stage, combined with the lack
of effective therapies for advanced-stage disease [14,33,35,36].
The late diagnosis and the high rate of chemo-resistance of this
form of cancer proves a need for new therapeutic targets and a
better understanding of the mechanisms involved in the spread of
OC.
In the present study, we assessed the efficacy of Sp17
recombinant protein plus CpG in prophylactic and therapeutic
settings in the murine ID8 model. Sp17 has been shown here to be
expressed strongly in the cytoplasm and on surface membranes of
ID8 cells (by ICC, IF and flow cytometry). We were able to follow
tumor growth using Sp17 as a biomarker (figures 1 and 3). This
murine model generates ascites as shown in figures 3a and 3b, and
so it seems to reflect the pathology of the most aggressive and
Figure 6. (a,b) Measurement of cytokines in mice treated with different vaccines. On day 300, serum was collected and analyzed by
E.L.I.S.A. for the measurement of the indicated cytokine levels in prophylactically (a) or therapeutically (b) vaccinated mice. For both regimens, IFN-
gamma, TNF-alpha and GM-CSF statistically significant increments were detected only in Sp17+CpG vaccinated mice compared with controls (PBS).
No significant differences were evidenced for IL-2, IL-4, IL-5 or IL-10 levels.
doi:10.1371/journal.pone.0010471.g006
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generation of tumor nodes and fusion of the peritoneum also
resemble the human process (see figure 3b), as well as the typical
peritoneal localization evidenced in vivo by fluorescence imaging
(figure 3h). The use of this animal model has been reported for
different studies related to tumor targeting and vascular growth
factor [23,37], but this is the first time that a mouse counterpart of
a human tumor associated antigen, Sp17, has been shown to be
expressed in an OC mouse model.
One of the major criteria in deciding which candidate self-
antigen to target for prevention or therapeutic strategies is creating
an immune response in a safe manner, and the evidence here
suggests that Sp17 may be such a candidate. We have previously
shown that adoptively transferred Sp17-specific T cells have anti-
tumor activity [13,14,21,22], but Sp17-targeted therapeutic or
prophylactic vaccination has not been tested in a tumor model.
These results clearly indicate that the co-administration of
Sp17+CpG i.m. injected every 30 days for a total of ten
vaccinations prevented the formation of tumors up to 300 days,
with a survival rate of 77% for the prophylactic group and 80% for
the therapeutic vaccination group. Notably, the effects of the
vaccination in the prophylactic and therapeutic regimens were
similar. Both regimens induced a strong immunity that prevented
tumor growth in tumor-challenged mice. The mice that ultimately
succumbed to the disease showed delayed development of tumor
growth compared with the unvaccinated mice. We hypothesize
that our therapeutic regimen will be effective in rejecting
differently staged OC, since our therapeutic vaccinations did not
start until the ID8 tumors showed a significant growth, with
features usually observed in human stage III-IV OC, including
cancer spread beyond the pelvis, to the lining of the abdomen or to
the lymph nodes (www.ovariancancer.org) [38]. Tumor-injected,
unvaccinated animals displayed tumor spread to the peritoneum,
lymph-nodes, lungs, liver and spleen. Indeed, the mean difference
in weight between tumor-challenged and tumor-free groups was
10 grams, corresponding to about 50% mean animal weight
before tumor injections (20 grams).
The activation of a strong immune response against Sp17 was
demonstrated by ELISA and ELISPOT assays, showing an
increase in anti-Sp17 antibodies in mice serum, expression of
Th1-associated cytokines and tumor-specific cytotoxic responses.
It is noteworthy that no significant serological reactivity to Sp17
was detectable before vaccination, indicating the ability of the
vaccine to prime specific naı ¨ve B cells. Comparing the results of
Sp-17 specific antibody titers obtained with different therapeutic
vaccine formulations, we found only a small but evident increase
Figure 7. ELISPOT for the assessment of IFN-gamma and TNF-alpha serum levels. On day 270 (9
th vaccine) splenocytes from different
formulations of vaccinated mice and controls were collected and analyzed by E.L.I.SPOT assay. a,b) frequency of IFN-gamma and TNF-alpha positive
cells in prophylactic vaccinations; c,d) frequency of IFN-gamma and TNF-alpha positive cells in therapeutic vaccinations. These results are presented
as spot-forming cells per 10
6 splenocytes. Spot numbers represent the mean of ten mice in each vaccinated group; bars, SE.
doi:10.1371/journal.pone.0010471.g007
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animals compared with the other groups, especially following the
9
th vaccination. Therefore, we cannot judge whether tumor
rejection following CpG+Sp17 vaccinations can be attributed to
humoral responses. Given that the differences in antibody titers
between groups are small, we would conclude that the tumor
antigen-specific cellular immune responses we detected most
probably make a larger contribution to tumor rejection in
Figure 8. Cytotoxicity assay in the prophylaxis regimen. Splenocytes from the three different formulations of prophylactically vaccinated mice
and controls were collected and analyzed by
51Chromium-release assay on days 7 (first vaccine), 97 (third vaccine) and 270 (ninth vaccine), using
splenocytes as effector cells and ID8 as target cells. These results were obtained from three independent experiments. X axis indicate effector:target
ratios.
doi:10.1371/journal.pone.0010471.g008
Figure 9. Cytotoxicity assay in the therapeutic regimen. Splenocytes from the three different formulations of therapeutically vaccinated mice
and controls were collected and analyzed by
51Chromium-release assay. These results show three independent experiments after third vaccine (day
97) and ninth vaccine (day 270), using splenocytes as effector cells and ID8 as target cells. X axis indicate effector:target ratios.
doi:10.1371/journal.pone.0010471.g009
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istration of Sp17+CpG was better than Sp17 alone or CpG alone
as an adjuvant. It has been well documented that i.m. injections of
proteins generally do not induce significant immune responses
unless they are mixed with adjuvants [30,32,39]. Effective
adjuvants display at least 2 mechanisms of action: a depot effect
that leads to prolonged antigen exposure in the host, and a
capacity to trigger the innate immune system through activation of
dendritic cells (DC) via toll-like receptors (TLRs)[35]. Upon
proper antigen presentation, activated DC play a key role in the
induction of T cell responses[29,34,40,41,42]. Because of their
high efficacy, several recently identified TLR ligands are
promising vaccine adjuvants. Synthetic ODNs containing un-
methylated CpG dinucleotides flanked by two 59 purines and two
39 pyrimidines (CpG motif) have been reported to have
immunomodulatory activities[30]. CpG motifs potently enhance
T cell responses in multiple murine vaccination mod-
els[30,31,32,33,39]. By binding toll-like receptors, CpG can
activate DC and macrophages to trigger the production of IL-1,
IL-6, IL-12, and TNF-a, and lymphocytes, to produce IFN-c.
Overall, CpG DNA stimulates Th1-type responses, characterized
by IL-12 and IFN-c secretion with very little secretion of Th2
cytokines and a predominance of IgG2a over IgG1 in the mouse
[27,30,32,39,43,44]. We detected increased levels of TNF-alpha,
INF-gamma and GM-CSF in the serum of animals treated with
CpG+Sp17: this suggests a Th1 bias that is in accordance with the
expected CpG adjuvant activity [27,30,32,39,43,44]. Thus,
although not formally demonstrated, the most likely source would
be CD4+ Th1 T cells, and possibly CD8
+ T cells.
Sp17 is a known cancer testis antigen [22] and has already been
studied for OC T cell therapy [22,36], showing potential
application in its treatment. The cytotoxicity assays in this study
showed strong anti-tumor responses in the Sp17+CpG vaccinated
mice compared to the Sp17 and CpG immunized mice, both in
prophylactic and therapeutic vaccinations. Vaccination with Sp17
protein in the absence of CpG resulted in weak cytotoxic responses
and lack of anti-tumor effects in C57BL/6 mice indicating that
CpG serves a critical role in generating effective tumor-specific
cytotoxic responses and humoral responses. The killing assay
showed significant differences at a high E:T ratio (100:1); however,
since the effector cells were whole splenocytes and the frequency of
anti-tumor CTL in total splenocytes in the absence of a secondary
in vitro stimulation is likely to be very low [41,42], high E:T ratios
are usually required to detect cytotoxic activity.
The Sp17+CpG vaccination did not induce significant side
effects associated with inflammatory infiltration of normal tissues.
Our goal was also to provide a better understanding of the role
played by immunosurveillance in OC biology and progression.
Thus, we further extended our analysis to better characterize
the cell-mediated anti-tumor responses elicited by Sp17+CpG
vaccine. We detected a significant increase in CTL-stimulatory
Th-17 cells and a decrease in immunosuppressive T-reg cells in
vaccinated mice compared with non vaccinated tumor-bearing
mice in both prophylactic and therapeutic regimens. This suggests
that our Sp17-based vaccine formulation could have the potential
to prevent the activation of immunosuppressive mechanisms that
has been reported after systemic treatment with high-doses CpG
and can potentially represent a major obstacle in the use of ODN-
adjuvanted vaccines [40]. Although it has been recently shown
that epithelial ovarian cancer-associated CD4
+ regulatory T
lymphocytes are characterized by a notable plasticity and can be
reprogrammed into functional Th-17
+ cells in vitro [45], it is known
that Th-17
+ and Foxp3
+ T cells can originate from naı ¨ve CD4
+
lymphocytes with high frequencies [46,47,48,49] in vivo: this is in
accordance with our finding that vaccines consisting in Sp17 or
CpG administered alone induced a marked decrease in T-reg
population frequency, with even higher degree than combined
Sp17+CpG did in both therapeutic and prophylactic regimens,
but were unable to significantly increase the occurrence of Th-17
+
cells, as prophylactic or therapeutic combined Sp17+CpG. Since
Figure 10. Analysis of Th-17 and T-reg population frequencies. Splenocytes from mice that received prophylactic or therapeutic vaccinations
or controls (mice with no tumor or tumor-bearing mice without vaccinations) were collected at different time points (no tumor: day 0; ID8 only: day
45; prophylactic and therapeutic vaccines: day 270) analyzed by flow-cytometry for the measurement of a) Th-17 population (CD4/IL-17-double
positive) or b)T-reg population (CD4/Foxp3-double positive) frequency.
doi:10.1371/journal.pone.0010471.g010
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OC tumors, we hypothesized that a reduction in T-reg population
alone without a significant increment in Th-17
+ population is not
sufficient to raise effective anti-tumor immune surveillance.
Although some recent reports suggest that the presence of Th-
17
+ cells may contribute to tumor promotion [50,51], other studies
provide strong evidence that Th-17 T cell responses correlate with
antitumor activity [30,42,52,53,54]. Notable studies from Restifo
and colleagues have shown that adoptively transferred CD4
+ Th17
cells were markedly more effective than CD4
+ Th1 cells in
eradication of advanced B16 melanoma in a mouse model [55].
Of particular significance, recent clinical investigation has shown
that Th17 cell infiltration in ovarian tumors has a strong positive
correlation with prolonged overall survival [56], an observation
that stands in sharp contrast to the known association of Treg
infiltration with poor prognosis and increased mortality in ovarian
cancer patients [57].
Our results suggest that our vaccine formulation has the ability to
redirect T lymphocyte activation from suppressor T-reg to activator
Th-17 phenotype in vivo, in accordance with the findings by Paeseand
colleagues [58]. This possibility is intriguing for translation to clinical
settings since in ovarian carcinoma patients tumor lesions have been
shown to specifically recruit CD4
+CD25
+Foxp3
+ T-reg cells, while
tumor-infiltrating Th-17 cells recruit effector T cells to the tumor
microenvironment and their levels positively correlate with clinical
outcome. Accordingly, it has been proposed that vaccine strategies
promoting Th-17 responses may achieve effective tumor control and
increased survival in OC patients [54,59]. Further, no effective
prophylactic OC vaccines have been developed to date for the
prevention of the disease in high-risk women. Therefore, we believe
that our results provide the rationale for a paradigm shift in planning
OC immunotherapy, showing that the Sp17 prophylactic and
therapeutic vaccinations are capable of long-term protection against
tumor onset, progression and dissemination. The innovative
strategies we presented here are likely to be successfully used in
tandem with standard treatment for the cure of primary and
metastatic/recidivated OC and for tumor onset prevention in
patients with a family history of the disease or genetic predisposition.
Materials and Methods
Mice
Six-week-old female C57BL/6 mice were obtained from the
Jackson Laboratory (Bar Harbor, ME). Approval for the study was
obtained from the local Institutional Animal Care & Use
Committee. All mice were maintained in filtered-air laminar-flow
cabinets under specific pathogen-free conditions. Treatment and
care of the animals were in accordance with Institutional
Guidelines and the Animal Welfare Assurance Act.
Oligodeoxynucleotides
Both ODN 1826 (TCCATGACGTTCCTGACGTT) and non-
CpG ODN 1982 (TCCAGGACTTCTCTCAGGTT) were phos-
phorothioate modified and synthesized by Invitrogen (Carlsbad, CA).
ODNs were diluted in endotoxin-free water (Invitrogen).
Construction of pQE30/Sp17 recombinant expression
vectors
A primer pair, P1 (59-GGATCC ATGTCGATTCCTTTCTC-
39) and P2 (59-GGTACCTCAATTGTCTGCCTCTTC-39), was
designed based on the nucleotide sequence of the Sp17 mouse
gene. The amplified fragment was purified and subsequently
digested with Bam HI and Kpn I (Promega, Madison, WI) and
ligated with vectors pQE30 to construct the recombinant vectors
pQE30/Sp17 m according to standard methods. Escherichia coli
(M15) was transformed with the resulting ligation mixture, and the
transformed colonies were selected on medium containing
ampicillin and kanamycin, and confirmed by sequencing.
Expression and purification of Sp17 recombinant
proteins
The recombinant Sp17 was made as previously described [25].
Briefly, Escherichia coli(M15) cells transformed with pQE30/sp17 m
were propagated overnight in LB medium containing ampicillin
(50 mg/L) and kanamycin (50 mg/L) at 37uC with shaking over
night. The next day, 1 mL of the overnight culture was inoculated
into 100 mL of fresh LB medium plus antibiotics and the culture
was allowed to grow to an optical density of 0.6 at 600 nm
absorbance. The culture was induced with 1 mM IPTG and
grown for an additional 4 hours at 37uC. The cells were harvested
by centrifugation at 2,0006g for 10 minutes. The recombinant
Sp17 protein was purified using the Ni-NTA fast start kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. The
protein was tested for endotoxins and it was endotoxin-free, as
assayed through the Endotoxin Colorimetric Assay Kit, HEK-
Blue
TM (InvivoGen). Purity was confirmed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Western blot analysis
The protein concentration from cells or tissues was quantified
by Bradford assay (Bio-Rad). 25 mg of protein was resolved by
SDS-PAGE, and then transferred to a PVDF membrane. After
blocking, the membrane was incubated with primary mouse
monoclonal anti-Sp17 antibody [22], and then washed and
incubated with a horseradish peroxidase-conjugated secondary
antibody (Amersham). After washing, the membrane was
incubated in ECL (Enhanced Chemiluminescence, Amersham),
then exposed to imaging film (Amersham) [20,24].
Cell lines
The murine OC cell line ID8 (kindly provided by Dr. Roby,
University of Kansas) was cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and penicillin/
streptomycin (10 mg/mL of each) in 5% CO2 at 37uC, and used
within 20 passages after the initiation of the culture. Prior to
injection, cells were detached from flasks by exposing them to
0.25% trypsin/PBS/EDTA for 3 minutes. ID8 cell lines were
washed once and then suspended in PBS, counted, and adjusted to
the appropriate densities as single cell suspensions prior to
inoculation. For the evaluation of MHC-I expression, cells were
cultured in the presence or in the absence of 100 IU/mL mouse
IFN-c (R&D Systems).
In vivo determination of ID8 cell dose and cell injection
10
5,5 610
5,1 0
6,o r2 610
6 ID8 cells were i.p. injected into
groups of C57BL/6 mice (five mice per group). Each set of
experimental inoculations was performed at least three times,
independently. The ID8 cells were i.p. injected at day 70 after the
first tumor i.p injection. A group of control and one of tumor
injected animals were euthanized 45 days later for a post mortem
examination on the whole animals and dissected organs.
Peritoneal tumor masses and ascitic fluid specimens were collected
for further investigations.
In vitro tumor cell identification
To detect ID8 cells at distal sites to that of the injection, Sp17
was identified at the mRNA level by reverse transcription-
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immunohistochemistry (IHC), immunofluorescence (IF) and
Western blot.
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
Total RNA was extracted from cells and organs of healthy
control mice, and vaccinated and unvaccinated mice by means of
Tri-reagent (Sigma, St Louis, MO). All total RNA specimens were
treated with 5 mg of RNase–free DNase I (Promega) at 37uC for
2 hours. mRNA was then separated by using Oligotex mRNA
Mini Kit (QIAGEN, Valencia, CA). First-strand complementary
DNA (cDNA) synthesis was performed by using oligo (dT) 15
primers that amplify cDNA of approximately 500 base pairs (bp).
The PCR primers for Sp17 were as follows: 59-GGCAGT TCT
TAC CAAGAAGAT-39 and 59-GGA GGT AAA ACC AGT
GTC CTC-39. PCR was performed by means of 35 amplification
cycles at an annealing temperature of 57uC. Two positive control
amplifications (containing the cDNA of testis and the pQE30/
Sp17 plasmid) and negative controls for the PCR reaction mixture
(water) were also performed each time. RNA integrity in each
sample was checked by PCR amplification of a b-actin gene
segment. Successful removal of genomic DNA contamination was
confirmed in each sample by amplification of the RNA without
prior reverse-transcription. PCR products were visualized on an
ethidium bromide agarose gel for a DNA band of the expected
size, using an ultraviolet light trans-illuminator. All results were
confirmed by four independent RT-PCRs.
Immunization and tumor challenge
Female C57BL/6 mice (6 weeks old) were immunized i.m. with
50 mg Sp17 protein (in 20 ml of sterile water) and 20 mg CpG (in
20 mL of sterile water). The mice were injected every 30 days for a
total of 300 days. As control groups, the mice were vaccinated with
50 mg Sp17 protein only or 20 mg CpG only. 70 days after the first
vaccination, mice were challenged i.p. with the optimal dose of
2610
6 ID8 murine OC cells. Survival was followed until tumors
reached volumes of .1,000 mm
3.
Immunohistochemistry (IHC)
Tumor tissue was treated by the freezing tissue procedure, or
tissue in paraffin, and 30% of the tissue organs were prepared as
single cell suspensions and stored at 220uC [30]. After
deparaffining and re-hydration, antigen retrieval was performed
in a thermostatic bath (Fisher Scientific, Pittsburgh, PA) at 98uC
for 30 minutes in a freshly prepared 1 mM EDTA solution. After
15 minutes incubation in a 3% H2O2 solution, the sections were
exposed for 1 hour at room temperature to the primary mouse
monoclonal anti-human Sp17 antibody [17,22], diluted in TBS +
BSA (0.2%) + NaN3 (0.02%), or to 1 mg/mL mouse IgG1
(DAKO, Carpinteria, CA) as a negative control. After washing 3
times for 5 minutes in TBS + Tween 20%, sections were incubated
for 30 minutes with the secondary antibody (Envision system,
DAKO) followed by 5 minutes dark incubation with DAB system
(DAKO), performed to visualize brown precipitates as reaction
results. Cells were counter-stained with hematoxylin (Fisher
Scientific) and results were evaluated by light microscope [30].
Immunocytochemistry/Immunofluorescence (ICC/IF)
A standardized technique for detecting Sp17 in ID8 cells was
performed as previously described [21,22]. Briefly, an ID8 single
cell suspension was counted (5610
4 cells/100 mL) and washed
with PBS. Afterwards, slides were set up with a filter card and
introduced into the Shandon Cytospin-2 and spun at 800 rpm for
three minutes. The funnel and filter were removed from the glass
slides, fixed with SlideRite (Fisher Scientific) and the cells were
allowed to air-dry overnight. 5610cells were permeabilized with
0.5% Triton X-100 (Sigma Ltd, St. Louis, MO, USA) 0.1%
sodium citrate in PBS at 4uC for 15 minutes. Cells were then
treated with either primary mouse antibodies raised against
human Sp17 (mouse monoclonal anti-human Sp17 antibody
[30], dilution 1:400 in PBS) at room temperature for two hours, or
with 1 mg/mL mouse IgG1 (DAKO) as a negative control. This
was followed by 30 minutes incubation with the Envision System
(DAKO). The DAB system (DAKO) was used to yield brown
reaction products in the case of ICC, while FITC conjugated
rabbit IgG secondary antibody (Abcam, Cambridge, MA) was
used to bind the primary antibody for IF. The immunocytochem-
ical reactions were observed using a light microscope [30]. For IF,
results were analyzed using an Olympus IX71 inverted microscope
equipped with a Fluoview 300 confocal laser system (Olympus,
Center Valley, PA).
Cytotoxicity assays
Standard 4-hour
51Cr-release assays were performed to
determine the cytotoxic activity of the Sp17-stimulated spleno-
cytes. The ID8 target cells endogenously express Sp17. All
experiments were set up in quadruplicates and repeated at least
three times. Standard deviations (SD) were determined based on
the quadruplicates. For all targets, cell viability was .90% with
the maximum release in excess of 2000 cpm and the spontaneous
release ,30% of the maximum release.
ELISPOT- CD8 T cell assay
Immune responses generated by the vaccines were measured
using ELISPOT assays to detect CD8 T cells secreting IFN-c
(Mabtech, Inc., Mariemont, OH) using purified CD8 T cells
(Miltenyi Biotech, Auburn, CA). Serial dilutions of CD8 T cells
were tested against 3610
6 stimulator cells. Spot counting was done
with an AID ELISPOT Reader System (Cell Technology, Inc.,
Columbia, MD).
ELISPOT IFN-c and TNF-a Assays
Cytokine expression by T cells from the immunized animals was
evaluated using the ELISPOT assay (U-CyTech, Utrecht, The
Netherlands) according to the instruction manual. Briefly, the 96-
well filtration plates (Millipore, Bedford, MA) were coated with
100 ml diluted antibodies. After overnight incubation at 4uC, the
wells were washed and blocked with washing and blocking buffer.
T cells from the spleens of vaccinated mice (3610
6 cells/mL) were
added to triplicate wells and incubated with 20 mg/mL Sp17
protein at 37uC in an atmosphere of 5% CO2 for 48 hours.
Positive control wells were added with Con-A (5 mg/mL), and
background wells were added with RPMI 1640 medium. The
plates were then washed extensively (10 times) and incubated with
100 ml biotinylated detection antibodies at 4uC overnight. After
washing six times, 50 ml diluted GABA was added and incubated
for 1 hour at 37uC and then washed twice. The spots were
developed by adding 30 ml Activator I/II solution and incubating
at room temperature for 25–30 minutes. Spot counting was done
with an AID ELISPOT Reader System (Cell Technology, Inc.,
Columbia, MD).
ELISA for Sp17 antibodies
Animals were vaccinated every 30 days and their blood samples
were collected before each injection. Briefly the 96-well plates were
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overnight at 4uC. After washing and blocking, the goat Sp17
polyclonal antibody as positive control or serial dilution of mice
sera were added and incubated at 37uC for 1 hour. After washing
with PBS/0.05% Tween-20, HRP-conjugated rabbit anti-goat
antibody (Abcam) was added and allowed to incubate at 37uC for
1 hour. The reaction was developed by adding TMB Microwell
substrate and stopped by 2 M H2SO4. The absorbance was read
at 450 nm.
ELISA for cytokines of the sera
Cytokine concentration determined from standard curves. Sera
from vaccinated mice were collected to measure Sp17 levels.
Serum cytokine levels were measured by using commercial ELISA
kits (R&D Systems, Minneapolis, MN), in accordance with the
manufacturer’s instructions. Briefly add 50 uL of Standard,
Control, or sample per well. Incubate for 2 hours at room
temperature. Plate layouts are provided to record standards and
samples assayed. After the last wash, add 100 uL of mouse
cytokines Conjugate to each well and Incubate for 2 hours at
room temperature. Repeat the aspiration/wash, then add 100 uL
of Substrate Solution to each well. Incubate for 30 minutes at
room temperature. Add 100 uL of Stop Solution to each well.
Gently tap the plate to ensure thorough mixing. Determine the
optical density of each well within 30 minutes, using a microplate
reader set to 450 nm.
Flow-cytometry
Flow-cytometric analyses were performed through BD FACS-
Canto
TM II Flow Cytometry System (BD Biosciences) and
CellQuest software. For analysis of ID8 cells, exponentially-
growing cells were detached with trypsin for 5 minutes, washed
twice in PBS supplemented with 1% BSA and fixed with 2%
paraformaldehyde at room temperature for 10 minutes. Then,
cells were washed twice in PBS/BSA and allowed to incubate for
1 hour on ice with anti-MHC-I antibody (Abcam) and mouse anti-
SP17 monoclonal antibody (developed in our lab). For analysis of
splenocytes, cells were washed twice in PBS, fixed with 2%
paraformaldehyde at room temperature, and then permeabilized
with 0.5% saponin for 10 minutes on ice. After washing with PBS,
anti-CD4-PE, Foxp3-PE (Abcam) and IL-17-Alexa FluorH 700
(BD Biosciences) were added and allowed to incubate for 1 hour
on ice. Then, cells were washed twice with PBS and analyzed.
Statistical analysis
Tumor growth and chromium release assay, ELISPOT assay,
ELISA assay and flowcytometry data were analyzed by a one-
tailed, paired Student’s test and survival rates were analyzed by
log-rank test. All statistical analyses were performed through
GraphPad Prism 5H (GraphPad Software, Inc., La Jolla, CA).
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